Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply on Monday.
Mereo BioPharma and its partner Ultragenyx revealed results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). Osteogenesis Imperfecta (OI) includes a group of genetic disorders impacting bone metabolism. The collagen mutations in OI can result in increased bone brittleness, which contributes to a high rate of fractures.
Ultragenyx Pharmaceutical shares dipped 42% to $19.84 on Monday.
Here are some other stocks moving in today’s mid-day session.
Now Read This:
Photo via Shutterstock